Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 6 of 59, showing 10 Applications out of 584 total, starting on record 51, ending on 60

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

51.

ECCT/25/05/12   SAFIRE
    A multicentre open-label, non-inferiority adaptive platform randomised controlled trial to evaluate the efficacy, safety, and tolerability of antimalarials for the treatment of uncomplicated malaria in the first trimester of pregnancy   
Principal Investigator(s)
1. Hellen Barsosio
Site(s) in Kenya
The Kenya Medical Research Institute (KEMRI), Centre for Global Health Research (CGHR)
 
15-10-2025 View

52.

ECCT/25/05/11   Sparkle study site-1406
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Doreen Mutua
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. Ahero Clinical trials Unit (Kisumu county)
3. International Cancer institute (Uasin Gishu county)
4. Kondele Childrens Hospital (Kisumu county)
5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county)
6. Gertrudes Children’s Hospital (Nairobi City county)
 
03-02-2026 View

53.

ECCT/25/05/10   Field Evaluation for STI POC
    Evaluation of a Point-of-Care (PoC) diagnostic device to improve sexually Transmitted Infections Management and outcomes in Kenya:   SERU PROTOCOL NO. NON KEMRI 5074   Enable GingerCannot connect to Ginger Check your internet connection  or reload the browserDisable Ginger?How to use GingerRephraseRephrase with Ginger (Ctrl+Alt+E)Edit in GingerGinger is checking your text for mistakes...Disable Ginger in this text fieldDisable Ginger on this website×   Enable GingerCannot connect to Ginger Check your internet connection  or reload the browserDisable Ginger?How to use GingerRephraseRephrase with Ginger (Ctrl+Alt+E)Edit in GingerGinger is checking your text for mistakes...Disable Ginger in this text fieldDisable Ginger on this website×   
Principal Investigator(s)
1. Patricia Ongwen
2. Dismas Ouma
3. Rose Wafula
Site(s) in Kenya
International Centre for Reproductive Health -Kenya
 
29-04-2026 View

54.

ECCT/25/05/08   Floral roll over study
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Prof Videlis Nduba
Site(s) in Kenya
1. KEMRI Siaya Clinical Research Annex (Siaya county)
2. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
3. Gertrudes Childrens Hospital (Nairobi City county)
4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
5. KEMRI WALTER REED KERICHO (Kericho county)
6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
7. KEMRI Kondele Children\'s Hospital (Kisumu county)
 
05-03-2026 View

55.

ECCT/25/05/07   Floral roll over study
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Prof Jessie Githanga
Site(s) in Kenya
1. Gertrudes Childrens Hospital (Nairobi City county)
2. KEMRI Kondele Children\'s Hospital (Kisumu county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
5. KEMRI WALTER REED KERICHO (Kericho county)
6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
7. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
 
21-11-2025 View

56.

ECCT/25/05/06   Hibiscus 2 - Site 254
    A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.   
Principal Investigator(s)
1. Doreen Mutua
Site(s) in Kenya
1. Site 254 - Gertrude\'s Children\'s Hospital (Nairobi City county)
 
26-11-2025 View

57.

ECCT/25/05/05   Hibiscus 2 - Site 252
    A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.   
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. KEMRI CRDR Siaya Clinical Research Annex (Siaya county)
 
15-10-2025 View

58.

ECCT/25/05/04   Floral roll over study
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Bernhard Ogutu
Site(s) in Kenya
1. KEMRI Kondele Children\'s Hospital (Kisumu county)
2. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
3. Gertrudes Childrens Hospital (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
5. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
6. KEMRI WALTER REED KERICHO (Kericho county)
7. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
 
09-12-2025 View

59.

ECCT/25/05/03   Hibiscus 2 - Site 253
    A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. Site 253 - International Cancer Institute (Uasin Gishu county)
 
25-11-2025 View

60.

ECCT/25/05/02   Hibiscus 2 - Site 251
    A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.   
Principal Investigator(s)
1. Bernhards Ogutu
Site(s) in Kenya
1. Site 251 - Ahero Clinical Trails Unit, CREATES Strathmore University (Kisumu county)
 
16-12-2025 View